Pink Sheet is part of the Business Intelligence Division of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By


Lobbying FDA: AbbVie Questions Humira Biosimilars In Private Meeting

Executive Summary

Switching, manufacturing, and indication extrapolation among worries raised in closed-door session where AbbVie argued Humira's mechanism of action is not entirely understood.


Related Content

Biosimilar Firms Fight Against 'Whisper Campaign' On Interchangeability
Biosimilar Firms Fight Against 'Whisper Campaign' On Interchangeability
Humira Biosimilar Interchangeability: The Race Begins
Biosimilar Labeling: Should FDA Just Throw Up Its Hands And Finalize Guidance?
AbbVie v. Amgen Round One: Humira Biosimilar Infringes 10 Patents, Suit Claims
Sandoz's Multi-Switch Biosimilar Trials: A View To Interchangeability?
Biosimilar Non-Medical Switching: Advocacy Groups, FDA Advisors Push For Action
Amgen's Humira Biosimilar Gains Nod From Panel Perplexed By Regulatory Pathway
Biosimilars: Does FDA Caution Make Advisory Committee A Rubber Stamp?
Biosimilar Manufacturer Reliability Is Key To Market Uptake, Amgen Says


Related Companies




Ask The Analyst

Please Note: You can also Click below Link for Ask the Analyst
Ask The Analyst

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts